AOD 9604 Peptide: The Fat-Burning HGH Fragment and What the Research Shows

Perfect B, Doral FL. | 04.03.26 | 10 min read.

This article is for educational purposes only and does not constitute medical advice. AOD 9604 is not FDA-approved as a pharmaceutical drug. Consult a licensed medical provider before beginning any peptide therapy.

What Is AOD 9604 Peptide and Why Is It Generating Clinical Interest?

AOD 9604 is a synthetic fragment of human growth hormone, specifically amino acids 176 through 191 of the hGH sequence, with a single modification at the N-terminus for stability. It was developed in the 1990s by researchers at Monash University in Melbourne, Australia, with one goal: isolate the fat-burning portion of growth hormone and deliver those effects without the risks that come with full hGH administration.

The result is a 16-amino acid peptide that stimulates lipolysis through beta-3 adrenergic receptors on fat cells, without triggering IGF-1 elevation, insulin resistance, or the growth-promoting effects that make full HGH problematic for long-term metabolic use. For patients in Miami who are exploring options beyond GLP-1 medications, this mechanism is clinically meaningful.

At Perfect B in Doral, FL, we are currently in an internal evaluation phase with AOD 9604. We do not yet offer it to patients, but our clinical team has been reviewing the research closely and running a structured internal protocol. What follows is what we know from that review and from the published clinical record.

Key Takeaways

• AOD 9604 is a fragment of HGH (amino acids 176-191), not a complete hormone. It targets fat metabolism without the insulin or IGF-1 effects of full growth hormone.
• Six Phase I/II clinical trials enrolling approximately 900 participants confirmed an excellent safety profile with no serious adverse events attributed to the compound.
• The standard research protocol is 300 mcg per day, subcutaneous, administered in a fasted state, typically in the morning before food or exercise.
• AOD 9604 does not suppress appetite the way GLP-1 medications do. Its mechanism is direct lipolysis, making it a different tool with different patient profiles.
• Perfect B is currently evaluating AOD 9604 internally and does not yet offer it to patients. When we do, it will be within a supervised clinical framework.

How AOD 9604 Works at the Molecular Level

The lipolytic activity of growth hormone has been understood since the 1960s. What made AOD 9604 compelling was the identification that a specific region of the hGH molecule, the C-terminal fragment, was responsible for this fat-burning effect, and that this region operated through a pathway separate from the growth hormone receptor.

AOD 9604 binds to beta-3 adrenergic receptors located on adipocytes (fat cells). Activation of these receptors triggers two complementary processes: it accelerates lipolysis (the breakdown of stored triglycerides into free fatty acids for energy) while simultaneously inhibiting lipogenesis (the conversion of glucose and other substrates into new fat stores). The net result is a shift toward fat oxidation rather than fat storage.

Crucially, this happens without IGF-1 stimulation. IGF-1 elevation is the primary mechanism through which full HGH increases the risk of insulin resistance, fluid retention, and certain growth-related effects at high doses. Because AOD 9604 does not bind the growth hormone receptor, it does not trigger the IGF-1 cascade. In rodent knockout models where beta-3 adrenergic receptors were removed, the lipolytic response to AOD 9604 was eliminated, confirming the receptor-specific mechanism.

What This Means Clinically

For patients who have tried GLP-1 medications and experienced significant side effects, or who are not candidates for appetite-suppressing approaches, AOD 9604 represents a mechanistically different option. It does not reduce appetite. It does not affect gastric emptying. Its effect is specific to adipose tissue metabolism. That specificity is both its strength and its limitation.

AOD 9604 Clinical Trial History: What the Research Actually Shows

Six Phase I and Phase II clinical trials were conducted by Metabolic Pharmaceuticals Ltd., enrolling approximately 900 participants in total. The trials tested oral, intravenous, and subcutaneous routes of administration at doses ranging from micrograms to 1 mg per day. Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption.

The most clinically relevant efficacy data came from METAOD005, a 12-week randomized double-blind placebo-controlled study. Participants receiving 1 mg per day of AOD 9604 lost approximately 2.6 kg compared to 0.8 kg in the placebo group. The finding was statistically significant. The follow-up pivotal trial (METAOD006 / OPTIONS) enrolled a larger cohort and failed to replicate statistically significant weight loss, which led Metabolic Pharmaceuticals to halt the formal drug development program in 2007.

The compound then received GRAS (Generally Recognized as Safe) designation from the FDA for use as a food ingredient, which is a separate regulatory category from drug approval. It remains an investigational peptide, not an approved pharmaceutical.

A peer-reviewed study in the Journal of Endocrinology confirming that AOD9604 produces lipolysis and increases fat oxidation in obese mice via the beta-adrenergic pathway, with effects comparable to full-length HGH but without the insulin-disrupting side effects provided early mechanistic validation that informed the human trials. Additionally, research published in Drug Testing and Analysis characterizing AOD9604 metabolism and confirming its C-terminal HGH fragment structure, supporting its classification as a non-IGF-1-stimulating lipolytic agent has been used by clinicians evaluating the compound for metabolic applications.

AOD 9604 vs Semaglutide (GLP-1): They Are Not the Same Tool

The rise of GLP-1 medications like semaglutide has reshaped how Miami patients approach medically supervised weight management. But the mechanism of GLP-1 agonists is fundamentally different from AOD 9604, and comparing them directly misses the point.

• Mechanism: Semaglutide works primarily through appetite suppression by acting on GLP-1 receptors in the brain and gut. AOD 9604 works through direct activation of fat cell receptors, bypassing appetite signaling entirely.
• Side effects: GLP-1 medications are frequently associated with nausea, constipation, gastroparesis, and, in some patients, significant muscle mass loss alongside fat loss. AOD 9604 clinical trials showed a tolerability profile statistically indistinguishable from placebo.
• Muscle preservation: Because AOD 9604 targets adipose tissue specifically and does not suppress systemic anabolic signaling, researchers have hypothesized that it may allow for fat loss with less collateral impact on lean mass, though this has not been formally tested in head-to-head trials.
• FDA status: Semaglutide is FDA-approved. AOD 9604 is not. This is a meaningful clinical distinction that any responsible provider must communicate.
• Patient overlap: In a clinical setting, these tools are not either/or. There is a theoretical case for using both in certain patients, targeting different physiological mechanisms simultaneously, though this approach is under evaluation and not yet standard of care.

AOD 9604 Dosage and Protocol: What the Research Supports

The standard research protocol for AOD 9604 is 300 mcg per day, administered via subcutaneous injection. Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded.

Standard Research Protocol

• Dose: 300 mcg per day subcutaneous injection
• Timing: Morning, fasted state (at least 30 minutes before food or exercise for maximal absorption)
• Cycle length: Typically 8 to 12 weeks on, followed by a 4-week rest period
• Reconstitution: Standard BAC water reconstitution; follow sterile compounding guidelines
• Injection site: Abdomen subcutaneous, rotating sites each injection
• Stacking: Often evaluated in combination with CJC-1295/Ipamorelin for complementary anabolic-lipolytic effects, or with BPC-157 for tissue repair support

These parameters reflect research protocols and published clinical trial data. Actual dosing for any patient must be determined by a licensed medical provider based on individual health history, body composition goals, and concurrent treatments. At Perfect B, when we introduce AOD 9604 to our clinical offerings, it will be prescribed within a monitored protocol, not as a standalone over-the-counter supplement.

AOD 9604 Before and After: What Results Actually Look Like

The “before and after” framing that patients often search for is understandable but requires clinical context. AOD 9604 is not a dramatic body recomposition tool on its own. The published data shows meaningful but modest fat loss in clinical conditions, approximately 1 to 2 kg of additional fat loss over 12 weeks compared to placebo at 1 mg/day. At 300 mcg, which is the standard current protocol, the effect size is likely more modest still.

Where AOD 9604 may show more pronounced results is in the context of a structured program that includes caloric management, resistance training, and potentially stacked peptide protocols. Several clinicians working with investigational peptides report that AOD 9604 appears most effective when the patient is already in a mild caloric deficit and performing regular exercise, as the free fatty acids liberated by the lipolytic process need to be oxidized, not re-stored.

What Patients Evaluating AOD 9604 Typically Report

• Timeline to first changes: Most published protocols note 4 to 6 weeks before body composition changes become measurable
• Areas of change: Visceral and subcutaneous fat reduction, with particular effect reported in the abdominal region in some subjects
• Energy and recovery: Some participants in clinical and investigational settings report improved energy and exercise recovery, though this is not a primary mechanism of the peptide
• What it is not: AOD 9604 does not cause rapid dramatic weight loss the way GLP-1 medications can in the first few months. Its effect is more targeted and incremental.

AOD 9604 Side Effects: What Six Clinical Trials Found

The safety data on AOD 9604 is stronger than for most investigational peptides, precisely because six formal clinical trials were conducted before development halted. Across approximately 900 participants, the adverse event profile was indistinguishable from placebo. No serious adverse events were attributed to the compound. No immunogenic responses. No changes in IGF-1. No glucose dysregulation. No cardiovascular signals.

The most commonly reported events in active arms were mild and transient: injection site reactions in some subcutaneous subjects, occasional headache, and in some oral dosing arms, minor gastrointestinal tolerance issues. All resolved without intervention.

The absence of IGF-1 stimulation is particularly relevant for long-term safety. IGF-1 elevation from full HGH use is associated with increased cell proliferation risk, fluid retention, and carpal tunnel syndrome at therapeutic doses. AOD 9604 does not share this risk profile.

That said, the compound has not been through full Phase III trials or FDA drug approval. Long-term safety beyond 12 weeks has not been formally studied in large populations. Patients with active malignancies, pregnancy, or significant hormonal imbalances should not use investigational peptides without specialist clearance.

Who Would Be a Good Candidate for AOD 9604 Therapy?

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised:

• Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat
• Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications
• Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program
• Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack
• Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns

AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome. In those patients, addressing the underlying metabolic dysfunction first, through dietary intervention, GLP-1 therapy if indicated, or NAD+ support for cellular energy metabolism, is the clinical priority.

→ Explore Perfect B’s supervised weight loss treatment plan at our Doral, FL clinic

Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective

We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option. GLP-1 drugs work through appetite suppression. Once that mechanism runs its course, or once the patient is off the medication, the underlying adipocyte metabolism is largely unchanged.

AOD 9604 operates on a different lever. If the safety and modest efficacy data from the published trials translate to our patient population, it would give us a tool that acts directly on fat cell metabolism rather than appetite, with a side effect profile that appears extremely well-tolerated. That is clinically meaningful for a specific subset of patients.

We are not yet offering AOD 9604 to patients. Our internal protocol is being monitored by our clinical team, and we will transition to patient-facing availability only when we are satisfied with our own observations and with the emerging evidence base. We mention it here because we believe patients deserve to know what is being evaluated at their clinic, and what the honest state of the evidence is, rather than hearing about it first from an online forum or supplement retailer.

If you are interested in being notified when AOD 9604 becomes available at our peptide therapy clinic in Doral, FL, you can reach our team directly at the contact below.

→ Learn about the peptide therapies currently available at Perfect B in Doral, FL

Stacking AOD 9604: Common Research Protocol Combinations

AOD 9604 is frequently evaluated in combination with other peptides, particularly in protocols designed for body recomposition rather than pure weight loss. The rationale for stacking is that different peptides operate through different mechanisms and do not typically compete or interfere with each other when used at standard doses.

AOD 9604 + CJC-1295 / Ipamorelin

This is the most commonly referenced research stack. CJC-1295 and Ipamorelin, both offered as part of Perfect B’s peptide treatment program, stimulate growth hormone release through GHRH and ghrelin receptor pathways. The combination creates a context where AOD 9604’s lipolytic effect is occurring simultaneously with GH-stimulated protein synthesis and recovery, theoretically allowing fat loss and lean mass preservation to happen in parallel.

AOD 9604 + NAD+

Combining AOD 9604 with NAD+ therapy at Perfect B in Doral targets two separate axes of metabolic function: NAD+ addresses cellular energy metabolism, mitochondrial efficiency, and metabolic resilience at the enzymatic level, while AOD 9604 drives fat mobilization from adipose tissue. For patients with fatigue alongside body composition concerns, this combination is conceptually compelling, though formal research on the combination is limited.

AOD 9604 + GHK-Cu

When body recomposition is the goal and skin quality or tissue repair is also a priority, AOD 9604 has been stacked with GHK-Cu in investigational settings. The copper peptide supports collagen synthesis and cellular repair while AOD 9604 drives lipolysis. For patients seeing skin laxity alongside fat loss, this stack addresses both processes simultaneously.

Frequently Asked Questions

1. Is AOD 9604 FDA-approved?

AOD 9604 is not FDA-approved as a pharmaceutical drug. It received GRAS (Generally Recognized as Safe) status for use as a food ingredient, which is a separate regulatory category. The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint. It remains an investigational peptide used in clinical and research settings outside of formal FDA-approved indications.

2. Does AOD 9604 cause muscle loss?

Based on the clinical trial data and the known mechanism, AOD 9604 does not appear to cause muscle loss. Its action is specific to adipocytes (fat cells) via beta-3 adrenergic receptors and does not affect anabolic pathways, protein synthesis signaling, or IGF-1 levels. This distinguishes it from GLP-1 medications, which in some patients have been associated with significant lean mass reduction alongside fat loss. That said, no formal head-to-head comparison of AOD 9604 versus GLP-1 agents for muscle preservation has been conducted.

3. How long does AOD 9604 take to work?

Based on investigational protocol reports and the clinical trial data, most subjects begin to see measurable changes in body composition at 4 to 6 weeks on a consistent daily protocol at 300 mcg. The 12-week trial showing 2.6 kg fat loss versus 0.8 kg placebo was run at 1 mg/day. At 300 mcg, the timeline may be longer. AOD 9604 is not a rapid intervention. Its effect is gradual and appears most pronounced when combined with a caloric deficit and regular physical activity.

4. Can AOD 9604 be stacked with semaglutide?

There is no published clinical data on the combination of AOD 9604 and semaglutide. Theoretically, they operate through different mechanisms: semaglutide suppresses appetite and slows gastric emptying via GLP-1 receptors, while AOD 9604 acts on beta-3 adrenergic receptors on fat cells. The mechanisms do not appear to contradict each other, and some researchers have speculated that combining them could address both appetite and direct fat cell metabolism. In practice, this combination would need to be evaluated by a supervising physician with careful monitoring.

5. Does Perfect B offer AOD 9604 to patients?

Not yet. We are currently in an internal evaluation phase, reviewing the published research and running a structured internal protocol with our clinical team. We do not offer AOD 9604 to patients at this time. When we transition to patient-facing availability, it will be within a supervised medical program, not as a self-directed supplement. Patients interested in being notified can contact our clinic directly.

6. What is the difference between AOD 9604 and HGH fragment 176-191?

They are the same compound. AOD 9604 (Anti-Obesity Drug 9604) is the commercial development name given to the HGH fragment spanning amino acids 176 through 191, with a tyrosine substitution at the N-terminus replacing the native phenylalanine for stability. The two terms are used interchangeably in clinical and research literature. Some compounding pharmacies and research sources list it as AOD-9604, AOD9604, or HGH Frag 176-191.

7. Is AOD 9604 safe for patients with diabetes or insulin resistance?

The clinical trial data is specifically reassuring on this point: across six trials involving approximately 900 participants, glucose levels, insulin levels, and markers of insulin sensitivity remained unchanged from baseline. This is a major differentiator from full HGH, which can worsen insulin resistance at therapeutic doses. That said, patients with active diabetes or significant metabolic dysfunction should have any investigational peptide protocol reviewed by their endocrinologist or primary care physician alongside their supervising aesthetic medicine provider.

The Clinic Takeaway: What AOD 9604 Means for South Florida Patients

AOD 9604 is not a weight loss miracle. It is a well-characterized, mechanistically specific peptide with a 30-year research history, a strong clinical safety record from formal trials, and modest but real efficacy data from 12-week studies. Its value in a clinical setting comes from what it is not: it does not disrupt appetite, hormones, insulin, or IGF-1. For the right patient, that profile matters.

At Perfect B in Doral, FL, we evaluate every emerging peptide through the same lens: does the mechanism make sense, does the safety data hold up under scrutiny, and does it give us a clinical tool that serves patients better than what we already offer? AOD 9604 meets the first two criteria clearly. We are working through the third. When we have a clinical answer, we will make it available, with full transparency about what it does and does not do.

• 📍 Perfect B | 3905 NW 107th Ave, Suite 104, Doral FL 33178
• 📞 Call or message us at (786) 502-2260 to schedule your peptide consultation with a licensed medical provider.
• 💳 Buy Now Pay Later: Cherry, Klarna, Afterpay, CareCredit

→ See Perfect B’s full weight loss and body recomposition treatment options in Doral, FL